APOL1 Genetic Testing in African Americans

RecruitingOBSERVATIONAL
Enrollment

600

Participants

Timeline

Start Date

January 24, 2019

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2027

Conditions
Genetic PredispositionChronic Kidney DiseasesNephropathyAPOL1 Associated Kidney DiseaseDisparities
Interventions
GENETIC

Assessment of the frequency of APOL-1 renal risk variant in the black population, and evaluating their attitudes about genetic testing and APOL1 genotype via self-administered surveys

On day of enrollment, participants will have 1 blood sample obtained to extract DNA for determining their APOL1 genotype, and will answer a survey asking about their attitudes/beliefs on kidney disease, hypertension, and diabetes, as well as genetic testing. Participants will receive their results via telephone shortly thereafter, and then complete the same survey at 3 months and 12 months post-enrollment, in order to evaluate if any of their attitudes or beliefs have changed since knowing their APOL1 genetic test result. Those who are interested, specifically those who carry the homozygous or compound heterozygous renal risk variant, will have the option to speak with a designated genetic counselor who is associated with the study site and approved by the IRB.

Trial Locations (1)

63104

RECRUITING

SSM Health Saint Louis University Hospital, St Louis

All Listed Sponsors
collaborator

Mid-America Transplant

OTHER

lead

St. Louis University

OTHER